Giant Cell Arteritis
Conditions
Keywords
Giant cell arteritis,, Tocilizumab, Aortitis, Remission
Brief summary
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA). Based on this rationale, several recent studies demonstrated the efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, for the treatment of patients with refractory GCA. Confirming previous reports,in a recent retrospective study the investigators successfully treated 10 patient with refractory GCA with TCZ. All patients achieved a complete disease remission evaluated by clinical, laboratory, and positron emission tomography (PET). In a considerable number of GCA patients treated with corticosteroids (CS) the therapy may be interrupted with no disease flares. No data are available on the management of patients achieving the remission with TCZ.
Detailed description
Study design. Open-label, prospective, pilot study on patients with giant cell arteritis (GCA) resistant to corticosteroids (CS) . Setting. Rheumatology department, Hospital of Prato, Prato, Italy. Treatment. All refractory GCA patients with or without involvement of aorta and its thoracic branches treated with intravenous TCZ at the dose of 8 mg/Kg/monthly or subcutaneous TCZ at the dose of 162 mg/weekly who achieved a stable remission over a 6-month period should receive reduced TCZ doses with the following schedules: intravenous TCZ tapering to 2 mg/Kg/monthly with drug withdrawal at month 4, and subcutaneous TCZ monthly reduction through the lengthening of injection intervals every 2, 3 , and 4 weeks, and with drug interruption at month 4. Primary end-point. To investigate the maintenance of clinical remission after TCZ interruption over a 6-month follow-up period. Secondary end-points. To assess the maintenance of clinical remission during the treatment, to evaluate the role of acute-phase reactants and PET in predicting the relapse and remission, and to assess the occurrence of adverse event (AEs).
Interventions
DRUGTocilizumab
Intravenous Tocilizumab followed by subcutaneousTocilizumab
Sponsors
Hospital of Prato
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
\- All consecutive patients meeting the 1990 ACR classification criteria for GCA.
Exclusion criteria
* Corticosteroid treatment during the previous 6 months. * Uncontrolled diabetes. * Uncontrolled hypertension. * History of cancer within the past 5 years. * History of frequent infections in the past. * Positivity of screening procedures for latent tuberculosis infection. * Uncontrolled dyslipidemia at baseline. * Known intestinal diverticulosis. * Concomitant hematologic disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients maintaining the off-therapy clinical remission over the follow-up as expressed by absence of GCA symptoms and signs, normal ESR and CRP values, absence of arterial wall inflammation at PET examination | 6-month off-therapy period | ESR ≤15 mm/h; CRP ≤0.5 mg/dl; VAS pain ≤10; PET: normalized SUVmax ≤1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients achieving and maintaining the clinical remission during the treatment with TCZ as expressed by the absence of GCA symptoms and signs, normal ESR and CRP values, absence of arterial wall inflammation at PET examination | 12 months | Absence of GCA symptoms and signs, ESR ≤15 mm/h, CRP ≤0.5 mg/dL, PET: normalized SUVmax ≤1 |
| To compare the role of acute-phase reactants and 18F-FDG-PET in the evaluation of remission. | Months 6,12,18 | Linear regression analysis for the correlation between ESR and CRP values and nSUVmax at baseline and after therapy |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 MeDRA 12.1. | Month 18 | Overall AEs and serious AEs will be recorded |
Countries
Italy
Outcome results
None listed